Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose
Pavord I., Bourdin A., Papi A., domingo C., Corren J., Altincatal A., Radwan A., Pandit-Abid N., Jacob-Nara JA., Deniz Y., Rowe P., Laws E., J DL., Hardin M.